On Friday, Inovio Pharmaceuticals (NYSEMKT:INO) announced that its shareholders had approved 1-for-4 reverse stock split of Inovio common stock. INO shares sank more than 5% in morning trading. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) weekly performance is -6.54%. On last trading day company shares ended up $2.00. Analysts mean target price for the company is $4.80. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -28.45%.
HC Wainwright initiated coverage on shares of OXiGENE (NASDAQ:OXGN) in a research report released on Tuesday morning, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $7.50 price objective on the stock. OXiGENE Inc. (NASDAQ:OXGN) shares fell -9.06% in last trading session and ended the day on $2.71. OXGN return on assets is -174.70%.OXiGENE Inc. (NASDAQ:OXGN) quarterly performance is 34.16%.
Sorrento Therapeutics (NASDAQ:SRNE) on 15 may announced that the U.S. Office of Orphan Products Development at the Food and Drug Administration (FDA) has approved the transfer of the Orphan Drug Designation sponsorship for its pain drug intrathecal resiniferatoxin (RTX). Sorrento Therapeutics Inc. (NASDAQ:SRNE) shares moved down -5.57% in last trading session and was closed at $4.92, while trading in range of $4.91 – $5.28. Sorrento Therapeutics Inc. (NASDAQ:SRNE) year to date (YTD) performance is -39.26%.
Questionable science behind Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) ORMD-0801 and its clinical trial results do not pass the smell test. Intense competition and pre-existing Big Pharma licensing and partnerships nullifies Oramed patent protection and reduces the likelihood of an acquisition. A bad management team with less-than-pristine backgrounds should be cause for alarm. Wolves of Wall Street in the employ of Oramed are targeting retail investors. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) ended the last trading day at $7.71. Company weekly volatility is calculated as 7.18% and price to cash ratio as 9.84.Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) showed a negative weekly performance of -18.59%.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a research and development company with a primary focus in ophthalmology, on 9 may announced the initiation of a Phase II investigator sponsored clinical trial, OHR-005, testing Squalamine Eye Drops in patients with diabetic macular edema (DME). OHR Pharmaceutical Inc. (NASDAQ:OHRP) weekly performance is -14.98%. On last trading day company shares ended up $7.55. Analysts mean target price for the company is $21.00. OHR Pharmaceutical Inc. (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is -34.32%.